News | January 31, 2025
Biocon posts Q3 FY25 PAT at Rs. 25 Cr
The group reported Q3FY25 operating revenue of Rs 3,821 crore, driven by sustained double-digit growth of 14 per cent in biosimilars
The group reported Q3FY25 operating revenue of Rs 3,821 crore, driven by sustained double-digit growth of 14 per cent in biosimilars
New capsule manufacturing lines added at Lonza Capsules & Health Ingredients (CHI) facilities in Rewari and Suzhou
The approved product has an estimated market size of US$ 106 million for the twelve months ending October 2024, according to IQVIA
Net Profit was at Rs. 10.04 crore, as compared to Rs. 5.12 crore in Q2 FY24, clocking a growth of 96.22%
JB’s domestic business continued to out-perform the market with all our major brands posting strong growth
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
Bortezomib Injection is approved for subcutaneous or intravenous use. It is available as a single dose vial of 3.5 mg/1.4 mL (2.5 mg/mL)
European markets now contribute 51% of our business revenue up from 43% in Q4 FY24 and 34% in Q1 FY24
EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year
Q1FY25 Revenue from Operations grew by 15% to Rs. 177 crore
Subscribe To Our Newsletter & Stay Updated
